Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 60.5%

Gross margin was 60.5% in Q3 FY2026, up 17.5 pp from a year earlier. On a trailing-twelve-month basis it was 53.2%, up 23.4 pp year over year.

Context

  • Gross margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
60.5%+4.4 pp QoQ
Last fiscal yearDec 2025
34.3%+9.9 pp YoY
LTMSep 2026
53.2%+23.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+17.5 pp——
1 year+9.9 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
34.3%
Year-over-year change
+9.9pp

Gross Margin vs competitors

How IOVA compares with its peers on the latest reported figures

  • IOVA's LTM Sep 2026 gross margin of 53.2% is the 7th highest of the 9 companies compared; the peer median is 64.1%.
  • Its year-over-year change of +23.4 pp is the 2nd highest of 8, against a peer median of -3.6 pp.
IOVA Competitors Peer median
Gross Margin for IOVA and competitors
Company Period LTM level YoY 3-year change
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
IBRXImmunityBio, Inc.LTM Sep 202696.7% +1.9 pp-0.7 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
IMNMImmunome, Inc.FY202557.4% -42.6 pp—
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 202653.2% +23.4 pp—
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
REPLReplimune Group, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding IOVA) 64.1%-3.6 pp-0.7 pp

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.